Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

Found 1430 recommendations for 667 medicines and 162 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
  1. BCG vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Ebola vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Japanese encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  4. Medicines for COVID-19 General information
    Section
    Medicines for COVID-19
    • Refer to WHO living guidelines
    Indications
    COVID-19
  5. Abacavir General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  6. Abacavir + dolutegravir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  7. Abacavir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  8. Abacavir + lamivudine + lopinavir + ritonavir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  9. Abemaciclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  10. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  11. Acamprosate calcium General information
    Section
    Medicines for alcohol use disorders
    • Oral > Solid > tablet: 333 mg
    Indications
    Disorders due to use of alcohol
  12. Acenocoumarol General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to warfarin for Venous thromboembolism Therapeutic equivalent to warfarin for Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin for Atrial fibrillation Therapeutic equivalent to warfarin for Other specified diseases of arteries or arterioles
  13. Acetazolamide General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
    Indications
    Primary open-angle glaucoma
  14. Acetic acid General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% solution
    Indications
    Infectious diseases of external ear
  15. Acetylcysteine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
    Indications
    Acute or subacute hepatic failure Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  16. Acetylsalicylic acid General information
    Section
    Medicines for acute migraine attacks
    • Oral > Solid: 300 to 500 mg
    Indications
    Migraine
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Indications
    Acute myocardial infarction Cerebral ischaemic stroke
    Section
    Medicines for juvenile joint diseases
    • Local > Rectal > Suppository: 150 mg; 300 mg
    • Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg
    • Oral > Solid > tablet: 75 to 500 mg
    Indications
    Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis Acute rheumatic fever without mention of heart involvement
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Pain
  17. Acetylsalicylic acid + atorvastatin + ramipril General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  18. Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  19. Aciclovir General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
    Indications
    Herpes simplex keratitis
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    Indications
    Zoster Herpes simplex infections Varicella
    Section
    Medicines for viral central nervous system infections
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    Indications
    Zoster Herpes simplex infections Varicella
  20. Aclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  21. Activated charcoal General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Liquid: 50 mg granules for oral suspension
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  22. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.
    Indications
    Psoriasis of unspecified type
  23. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  24. Albendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Echinococcosis Cysticercosis Hookworm diseases Trichuriasis Ascariasis Enterobiasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
    Indications
    Other specified echinococcosis Cysticercosis of central nervous system
    Section
    Antifilarials
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Lymphatic filariasis
  25. Alcohol based hand rub General information
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
    Indications
    Denatured alcohol
  26. Alcuronium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)
    Indications
    Muscle relaxants
  27. Alfacalcidol General information
    Section
    Medicines for endocrine disorders
    • Oral > Liquid: 2 µg per mL
    • Oral > Solid > capsule: 0.25 µg; 1 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  28. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  29. Allopurinol General information
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Gout
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  30. Alprostadil (prostaglandin E1) General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
    Indications
    Other specified congenital anomaly of great arteries including arterial duct
  31. Alteplase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Cerebral ischaemic stroke
  32. Amidotrizoate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
    Amidotrizoate
  33. Amikacin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neutropaenia (high-risk) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with cefotaxime Inflammatory or other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory or other diseases of prostate (severe)
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  34. Amiloride General information
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
    Indications
    Oedema Ascites
  35. Amiodarone General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  36. Amitriptyline General information
    Section
    Medicines for migraine prophylaxis
    • Oral > Solid > tablet: 25 mg
    Indications
    Migraine
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 25 mg per 5 mL
    • Oral > Solid > tablet: 25 mg; 10 mg; 75 mg
    Indications
    Palliative care
    Section
    Medicines for depressive disorders
    • Oral > Solid: 25 mg; 75 mg
    Indications
    Depressive disorders
  37. Amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
    Indications
    Essential hypertension
  38. Amodiaquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  39. Amodiaquine - sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package
    Indications
    Malaria
  40. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    Indications
    First choice
    Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site Infectious cystitis
    Section
    Medicines for bacterial central nervous system infections
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    Indications
    Second choice
    Bacterial meningitis
  41. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute sinusitis Other specified pneumonia (Hospital-acquired pneumonia) Chronic obstructive pulmonary disease with acute exacerbation Neutropaenia (low-risk) Peritoneal abscess (mild-moderate) Peritonitis (mild-moderate) Infectious cystitis Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Acute otitis media Other specified prophylactic measures Osteomyelitis or osteitis
    Other indications
    Bacterial infection of unspecified site
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  42. Amphotericin B General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Candidosis Blastomycosis Cryptococcosis Coccidioidomycosis Aspergillosis Sporotrichosis Histoplasmosis
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Visceral leishmaniasis
  43. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
    • Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Peritonitis (severe)
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Bacterial meningitis
  44. Anakinra General information
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe
    Indications
    Juvenile systemic arthritis
  45. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
    Section
    Ovulation inducers
    • Oral > Solid: 1 mg tablet
    Indications
    Therapeutic equivalent to letrozole for Female infertility without specification whether primary or secondary
  46. Anidulafungin General information
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin for Systemic or invasive candidosis
  47. Ansuvimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  48. Anti-D immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Maternal care for red cell antibodies Rh incompatibility reaction
  49. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  50. Anti-rabies virus monoclonal antibodies General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  51. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  52. Antirabies hyperimmune serum General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule
    Indications
    Rabies
  53. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  54. Antivenom sera General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  55. Apixaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Other specified atrial fibrillation Therapeutic equivalent to dabigatran for Venous thromboembolism
  56. Aprepitant General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid > capsule: 80 mg; 125 mg; 165 mg
    Indications
    Nausea or vomiting
  57. Aripiprazole General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone for Schizophrenia or other primary psychotic disorders
  58. Arpraziquantel General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > dispersible tablet: 150 mg
    Indications
    Therapeutic equivalent to praziquantel for Schistosomiasis
  59. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  60. Artemether General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  61. Artemether + lumefantrine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > dispersible tablet: 20 mg + 120 mg
    • Oral > Solid > tablet: 20 mg + 120 mg
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  62. Artesunate General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection
    • Local > Rectal > Other: 100 mg capsules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  63. Artesunate + amodiaquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg
    • Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  64. Artesunate + mefloquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  65. Artesunate + pyronaridine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)
    • Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  66. Artesunate - sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  67. Ascorbic acid General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Scurvy
  68. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    • Powder for injection: 10 000 IU in vial.
    Indications
    Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of unspecified sites
  69. Atazanavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  70. Atazanavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  71. Atenolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
    Essential hypertension Therapeutic equivalent to bisoprolol for Essential hypertension
  72. Atezolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Hepatocellular carcinoma of liver Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung
  73. Atoltivimab + maftivimab + odesivimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  74. Atorvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  75. Atorvastatin + perindopril + amlodipine General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  76. Atracurium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
    Therapeutic equivalent to vecuronium for Muscle relaxants Muscle relaxants
  77. Atropine General information
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
    Anterior uveitis
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)
    Indications
    Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
  78. Axicabtagene ciloleucel General information
    Section
    Antineoplastics and supportive medicines
    • Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.
    Indications
    Diffuse large B-cell lymphomas
  79. Axitinib General information
    Section
    Targeted therapies
    • Oral > Solid > tablet: 1 mg; 3 mg; 5 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  80. Azacitidine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Myeloid leukaemia
  81. Azathioprine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 50 mg (scored)
    Indications
    Rheumatoid arthritis, serology unspecified Psoriatic arthritis
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid > tablet: 50 mg (scored)
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 25 mg; 50 mg (scored)
    Indications
    Relapsing-remitting multiple sclerosis Failure or rejection of transplanted organs or tissues
  82. Azithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    Cholera Cholera [children] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws Trachoma co-prescribed with ceftriaxone Gonococcal infection
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Trachoma
  83. Aztreonam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified bacterial diseases
  84. Baclofen General information
    Section
    Medicines for cerebral palsy
    • Oral > Liquid: 10 mg per 5 mL
    • Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule
    • Oral > Solid > tablet: 10 mg
    Indications
    Spastic cerebral palsy
  85. Barium sulfate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
    Indications
    Barium sulfate with suspending agents
  86. Beclometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
    Indications
    Asthma Therapeutic equivalent to budesonide for Asthma
  87. Beclometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  88. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  89. Beinaglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity
  90. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  91. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
    Indications
    First choice
    Congenital syphilis [children] Syphilis
    Other indications
    Bacterial infection of unspecified site
  92. Benznidazole General information
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
    Indications
    Chagas disease
  93. Benzoic acid + salicylic acid General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 6% + 3%
    • Local > Topical > Ointment: 6% + 3%
    Indications
    Fungal infection of the skin
  94. Benzoyl peroxide General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
    Acne
  95. Benzyl benzoate General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
    Indications
    Pediculosis corporis Pediculosis capitis Pthiriasis Scabies
  96. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    Second choice
    Bacterial meningitis
  97. Beractant General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  98. Betamethasone General information
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
    Indications
    Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus
  99. Bevacizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
    Indications
    Hepatocellular carcinoma of liver
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age-related macular degeneration
  100. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  101. Binimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  102. Biperiden General information
    Section
    Medicines for parkinsonism
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
    Indications
    Parkinson disease
  103. Bisacodyl General information
    Section
    Laxatives
    Indications
    Therapeutic equivalent to senna for Constipation
  104. Bisoprolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Essential hypertension
    Section
    Medicines for migraine prophylaxis
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Migraine
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Cardiac arrhythmia
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Heart failure
  106. Blinatumomab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial
    Indications
    B lymphoblastic leukaemia or lymphoma, not elsewhere classified
  107. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  108. Brexpiprazole General information
    Section
    Medicines for depressive disorders
    • Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg
    Indications
    Depressive disorders
  109. Bromocriptine General information
    Section
    Medicines for central nervous system disorders
    • Oral > Solid: 2.5 mg; 5 mg
    Indications
    Parkinson disease
    Section
    Medicines for disorders of the pituitary hormone system
    Indications
    Therapeutic equivalent to cabergoline for Other specified benign neoplasm of endocrine glands
  110. Budesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler
    • Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler
    Indications
    Asthma
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 32 µg per actuation; 64 µg per actuation
    Indications
    Allergic rhinitis
  111. Budesonide + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler
    Indications
    Asthma
  112. Budesonide + salmeterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  113. Bumetanide General information
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide for Heart failure
  114. Bupivacaine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution
    • Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  115. Buprenorphine General information
    Section
    Medicines for opioid use disorders
    Indications
    Therapeutic equivalent to methadone for Opioid dependence
  116. Bupropion General information
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 150 mg sustained-release (hydrochloride)
    Indications
    Nicotine dependence
  117. C1 esterase inhibitor General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 500 IU in vial powder for injection
    Indications
    Hereditary angioedema
  118. Cabergoline General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
    Indications
    Other specified benign neoplasm of endocrine glands
    Section
    Medicines for central nervous system disorders
    • Oral > Solid > tablet: 0.5 mg
    Indications
    Parkinson disease
  119. Caffeine citrate General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    Indications
    Apnoea of newborn
  120. Calamine General information
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
    Pruritus
  121. Calcipotriol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 50 µg per mL (0.005%)
    • Local > Topical > Lotion: 50 µg per mL (0.005%)
    • Local > Topical > Ointment: 50 µg per mL (0.005%)
    Indications
    Psoriasis of unspecified type
  122. Calcitriol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type
    Section
    Medicines for endocrine disorders
    • Oral > Solid > capsule: 0.25 µg; 0.5 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  123. Calcium General information
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
    Indications
    Calcium deficiency
  124. Calcium folinate (leucovorin calcium) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    • Oral > Solid: 15 mg tablet
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
    Indications
    Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta
  125. Calcium gluconate General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Tetany due to acute calcium deficiency
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)
    Indications
    Hypermagnesaemia
  126. Canagliflozin General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  128. Capreomycin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  129. Captopril General information
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Heart failure
  130. Carbachol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    Indications
    Therapeutic equivalent to pilocarpine for Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine for Ocular hypertension Therapeutic equivalent to pilocarpine for Primary open-angle glaucoma
  131. Carbamazepine General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    Indications
    Epilepsy or seizures
    Section
    Medicines for neurological disorders
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    • Oral > Solid > capsule: 100 mg (extended-release); 200 mg (extended-release); 300 mg (extended-release)
    Indications
    Trigeminal neuralgia
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
    Indications
    Bipolar or related disorders
  132. Carbetocin General information
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
    Indications
    Postpartum haemorrhage
  133. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  134. Carboplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
    Indications
    Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of nasopharynx Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of breast Retinoblastoma Malignant neoplasms of kidney, except renal pelvis
  135. Carmellose General information
    Section
    Ophthalmological preparations
    Indications
    Therapeutic equivalent to hypromellose for Keratoconjunctivitis sicca
  136. Carvedilol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
  137. Caspofungin General information
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin for Systemic or invasive candidosis
  138. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    • Oral > Solid: 250 mg (as monohydrate)
    Indications
    First choice
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis
    Other indications
    Bacterial infection of unspecified site
  139. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
    Second choice
    Bacterial infection of joint Osteomyelitis or osteitis
    Other indications
    Surgical site infection
  140. Cefepime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection
    Indications
    Other specified bacterial diseases
  141. Cefiderocol General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli
  142. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection
  143. Cefotaxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
    Indications
    First choice
    Acute pyelonephritis (severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial pneumonia (Community-acquired pneumonia - severe) Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescribed with amikacin Inflammatory or other diseases of prostate (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe)
    Second choice
    Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis
    Other indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Bacterial meningitis
  144. Ceftaroline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection
    Indications
    Other specified bacterial diseases
  145. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    First choice
    Endophthalmitis
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic
  146. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli
  147. Ceftolozane + tazobactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  148. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Other specified pneumonia (Hospital-acquired pneumonia) Acute pyelonephritis (severe) Paratyphoid fever Typhoid fever Endophthalmitis Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial meningitis co-prescribed with amikacin Inflammatory or other diseases of prostate (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with metronidazole Necrotising fasciitis co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe)
    Second choice
    Acute pyelonephritis (mild to moderate) Bacterial infection of joint Sepsis without septic shock Infectious gastroenteritis or colitis without specification of infectious agent Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis
    Other indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Bacterial meningitis
  149. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Other specified prophylactic measures
  150. Cemiplimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung
  151. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab for Psoriasis of unspecified type
  152. Cetirizine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type
  154. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
    Second choice
    Bacterial meningitis
  155. Chlorhexidine General information
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Indications
    Omphalitis of newborn
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
    Chlorhexidine
  156. Chlorine base compound General information
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    • Local > Topical > Liquid: 0.1% available chlorine for solution
    • Local > Topical > Solid: 0.1% available chlorine for solution
    Indications
    Disinfectant, not elsewhere classified
  157. Chloroquine General information
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    • Oral > Liquid: 50 mg per 5 mL (base)
    • Oral > Solid > tablet: 150 mg (base)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
    Indications
    Rheumatoid arthritis
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Liquid: 50 mg per 5 mL (base)
    • Oral > Solid > tablet: 150 mg (base)
    Indications
    Malaria due to Plasmodium vivax
  158. Chlorothiazide General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  159. Chloroxylenol General information
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
    Indications
    Phenol disinfectant, not elsewhere classified
  160. Chlorpromazine General information
    Section
    Medicines for psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Therapeutic equivalent to haloperidol for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  161. Chlortalidone General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  162. Chlortetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma
  163. Cholera vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  164. Ciclesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  165. Ciclopirox General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan)
    Indications
    Onychomycosis
  166. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  167. Cimetidine General information
    Section
    Antiulcer medicines
    • Oral > Solid: 200 mg
    • Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule
    Indications
    Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  168. Ciprofloxacin General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
    Indications
    Infectious diseases of external ear
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    • Oral > Solid: 250 mg (as hydrochloride)
    Indications
    First choice
    Acute pyelonephritis (mild to moderate) Paratyphoid fever Typhoid fever Infectious gastroenteritis or colitis without specification of infectious agent Neutropaenia (low-risk) Inflammatory or other diseases of prostate (mild to moderate)
    Second choice
    Cholera Cholera [children] co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate)
    Other indications
    Bacterial infection of unspecified site
  169. Cisplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL
    • Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
    • Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of oropharynx Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Malignant neoplasms of nasopharynx Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites
  170. Citalopram General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
  171. Cladribine General information
    Section
    Medicines for multiple sclerosis
    • Oral > Solid > tablet: 10 mg
    Indications
    Multiple sclerosis
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
    Indications
    Langerhans cell histiocytosis
  172. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid > dosage form: 500 mg
    Indications
    First choice
    co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choice
    Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
    Other indications
    Helicobacter pylori associated gastric ulcer
  173. Clindamycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
    Indications
    First choice
    Necrotising fasciitis
    Second choice
    Bacterial infection of joint Osteomyelitis or osteitis
    Other indications
    Bacterial infection of unspecified site
  174. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Leprosy
  175. Clomifene General information
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
    Indications
    Female infertility without specification whether primary or secondary
  176. Clomipramine General information
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Obsessive-compulsive disorder
  177. Clonazepam General information
    Section
    Medicines for central nervous system disorders
    • Oral > Solid: 500 µg
    Indications
    Generalised myoclonic seizure
  178. Clopidogrel General information
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  179. Clotrimazole General information
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
    Indications
    Vulvovaginal candidosis
  180. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
    Indications
    First choice
    Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Sepsis without septic shock
    Other indications
    Bacterial infection of unspecified site
  181. Clozapine General information
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  182. Coagulation factor IX complex General information
    Section
    Coagulation factors
    Indications
    Therapeutic equivalent to coagulation factor IX, plasma-derived for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX, plasma-derived for Haemophilia B
  183. Coagulation factor IX, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  184. Coagulation factor IX, recombinant General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection
    Indications
    Haemophilia B
  185. Coagulation factor VIII, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  186. Coagulation factor VIII, recombinant General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection
    Indications
    Haemophilia A
  187. Coal tar General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Psoriasis of unspecified type
  188. Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  189. Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  190. Cobimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  191. Codeine General information
    Section
    Antitussives
    • Oral > Solid: 10 mg tablet (codeine phosphate)
    Indications
    Cough
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Pain
    Section
    Medicines for diarrhoea
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Diarrhoea
  192. Colchicine General information
    Section
    Medicines used to treat gout
    • Oral > Solid: 0.5 mg
    Indications
    Gout
  193. Colecalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
    Indications
    Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Calcium deficiency Therapeutic equivalent to ergocalciferol for Vitamin D deficiency
  194. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli
  195. Compound sodium lactate solution General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
    Indications
    Hypovolaemic shock Other specified disorders of fluid, electrolyte or acid-base balance
  197. Copper-containing intrauterine device General information
    Section
    Intrauterine devices
    • -
    Indications
    Contact with health services for insertion of contraceptive device
  198. Crizotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 200 mg; 250 mg
    • Oral > Solid: 200 mg; 250 mg
    Indications
    Anaplastic large cell lymphoma, ALK-positive Other specified malignant neoplasms of bronchus or lung
  200. Cryoprecipitate (pathogen-reduced) General information
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease
  201. Cyanocobalamin General information
    Section
    Antianaemia medicines
    • .
    Indications
    Anaemias or other erythrocyte disorders
  202. Cyclizine General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 50 mg per mL (lactate)
    • Oral > Solid > tablet: 50 mg (hydrochloride)
    Indications
    Palliative care
  203. Cyclopentolate General information
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine for Anterior uveitis
  204. Cyclophosphamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    • Oral > Solid: 25 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  205. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  207. Cytisine (cytisinicline) General information
    Section
    Medicines for nicotine use disorders
    • Oral > Solid > tablet: 1.5 mg
    Indications
    Nicotine dependence
  208. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Other specified atrial fibrillation Venous thromboembolism
  209. Dabrafenib General information
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
    Indications
    Other specified melanoma of skin
  210. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  211. Daclatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)
    Indications
    Chronic hepatitis C
  212. Daclatasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg
    Indications
    Chronic hepatitis C
  214. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  215. Dapagliflozin General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  216. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  217. Daptomycin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  218. Daratumumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
    Indications
    Plasma cell myeloma
  219. Darbepoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  220. Darunavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  221. Dasabuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 250 mg tablet
    Indications
    Chronic hepatitis C
  222. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myelogenous leukaemia, BCR-ABL1-positive
  223. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia
  224. Deferasirox General information
    Section
    Medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  225. Deferiprone General information
    Section
    Medicines for haemoglobinopathies
    Indications
    Therapeutic equivalent to deferasirox for Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox for Thalassaemias
  226. Deferoxamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
    Section
    Medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  227. Delafloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 300 mg lyophilized powder for injection
    • Oral > Solid: 450 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  228. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 25 mg
    • Oral > Solid > tablet: 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  229. Dengue vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  230. Desmopressin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 150 µg per actuation (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  231. Dexamethasone General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Indications
    Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy
    Section
    Hormones and antihormones
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base
    • Oral > Solid > tablet: 4 mg (as dexamethasone base)
    Indications
    Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equialent to 3.3 mg dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)
    Indications
    Nausea or vomiting
  232. Dextran 40 General information
    Section
    Plasma substitutes
    • .
    Indications
    Hypovolaemia
  233. Dextran 70 General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
    Hypovolaemia
  235. Diazepam General information
    Section
    Antiseizure medicines
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    Indications
    Therapeutic equivalent to lorazepam for Status epilepticus Status epilepticus
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    • Parenteral > General injections > unspecified: 5 mg per mL
    • Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored)
    Indications
    Palliative care
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Anxiety
  236. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  237. Dicloxacillin General information
    Section
    Access group antibiotics
    Indications
    First choice
    Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Therapeutic equivalent to cloxacillin for Sepsis without septic shock
  238. Didanosine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
    • Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  239. Diethylcarbamazine General information
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
    Indications
    Lymphatic filariasis
  240. Digitoxin General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
    • Oral > Solid: 50 µg; 100 µg
    Indications
    Heart failure
  241. Digoxin General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
    Cardiac arrhythmia
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
    Indications
    Heart failure
  242. Dihydroartemisinin + piperaquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)
    • Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  243. Dihydroergocryptine mesylate General information
    Section
    Medicines for central nervous system disorders
    • Oral > Solid:
    Indications
    Parkinson disease
  244. Diloxanide General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
    Amoebiasis
  245. Dimercaprol General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  246. Dinoprostone (prostaglandin E2) General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
    Indications
    Therapeutic equivalent to alprostadil (prostaglandin E1) for Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct
  247. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  248. Diphtheria vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  249. Diphtheria-pertussis-tetanus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria-tetanus-pertussis, combined
  250. Diphtheria-tetanus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against combinations of infectious diseases
  252. Docusate sodium General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL
    • Oral > Solid > capsule: 100 mg
    Indications
    Palliative care
  253. Dolasetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  254. Dolutegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  255. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  256. Donepezil General information
    Section
    Medicines for neurological disorders
    • Oral > Liquid: 1 mg per mL (hydrochloride)
    • Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)
    Indications
    Dementia due to Alzheimer disease
  257. Dopamine General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
    Indications
    Cardiogenic shock Heart failure
  258. Dostarlimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of corpus uteri
  259. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  260. Doxorubicin (as pegylated liposomal) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  261. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dosage form: 100 mg (as hyclate)
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
    Indications
    First choice
    Cholera Chlamydia trachomatis
    Second choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation
    Other indications
    Bacterial infection of unspecified site
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
    Indications
    Malaria due to Plasmodium falciparum
  262. Dulaglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  264. Edoxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Other specified atrial fibrillation Therapeutic equivalent to dabigatran for Venous thromboembolism
  265. Efavirenz General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  266. Efavirenz + emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  267. Efavirenz + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  268. Eflornithine General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
    Indications
    Gambiense trypanosomiasis
  269. Elbasvir + grazoprevir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 100 mg
    Indications
    Chronic hepatitis C
  270. Eletriptan General information
    Section
    Medicines for acute migraine attacks
    • Oral > Solid > tablet: 40 mg
    Indications
    Therapeutic equivalent to sumatriptan for Migraine
  271. Elexacaftor + tezacaftor + ivacaftor General information
    Section
    Medicines for cystic fibrosis
    • Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg
    • Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet
    Indications
    Cystic fibrosis
  272. Emicizumab General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial
    Indications
    Haemophilia A
  273. Empagliflozin General information
    Section
    Hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
    Indications
    Type 2 diabetes mellitus
  274. Emtricitabine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid: 200 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  275. Emtricitabine + rilpivirine + tenofovir alafenamide General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 25 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  276. Emtricitabine + rilpivirine + tenofovir disoproxil fumarate General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  277. Emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Contact with or exposure to human immunodeficiency virus Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  278. Emtricitabine + tenofovir alafenamide General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  279. Enalapril General information
    Section
    Antihypertensive medicines
    • Oral > Liquid: 1 mg per mL (as hydrogen maleate)
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Heart failure
  280. Encorafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  281. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  282. Entecavir General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  283. Enzalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 40 mg
    Indications
    Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate Malignant neoplasms of prostate
  284. Ephedrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
    Indications
    Cardiac complications of anaesthesia during labour or delivery
  285. Epinephrine General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Chronic obstructive pulmonary disease Asthma
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Anaphylaxis
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Cardiac arrest
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Indications
    Primary open-angle glaucoma
  286. Epoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  287. Epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  288. Epoetin theta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  289. Eptinezumab General information
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab for Chronic migraine
  290. Equine rabies immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  291. Eravacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg lyophilized powder for injection
    Indications
    Other carbapenem resistant Enterobacterales
  292. Erenumab General information
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab for Chronic migraine
  293. Ergocalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
    Indications
    Therapeutic equivalent to colecalciferol for Calcium deficiency Therapeutic equivalent to colecalciferol for Vitamin D deficiency Calcium deficiency Vitamin D deficiency
  294. Ergometrine General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
    Indications
    Postpartum haemorrhage
  295. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  296. Erythromycin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
    • Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
    • Oral > Solid: 250 mg (as stearate or ethylsuccinate)
    Indications
    Second choice
    Therapeutic equivalent to clarithromycin for Acute pharyngitis
    Other indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
    Indications
    Chlamydial conjunctivitis Gonococcal infection of eye
  297. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
    Section
    Supportive medicines
    • Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)
    Indications
    Drug-induced aplastic anaemia
  298. Escitalopram General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
  299. Estradiol General information
    Section
    Estrogens
    • Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg
    Indications
    Hypopituitarism Gonadotropin deficiency Turner syndrome
  300. Estradiol cypionate + medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
    Indications
    Contact with health services for reasons associated with reproduction
  301. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab for Psoriasis of unspecified type
  302. Ethambutol General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Other specified tuberculosis Tuberculosis
  303. Ethambutol + isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  304. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  305. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  306. Ethanol General information
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
    Indications
    Denatured alcohol
  307. Ether General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > solution:
    Indications
    Anaesthetics and therapeutic gases
  308. Ethinylestradiol + etonogestrel General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
    Indications
    Contact with health services for contraceptive management
  309. Ethinylestradiol + levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 50 µg + 250 µg [4]
    • Oral > Solid: 30 µg + 150 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
  310. Ethinylestradiol + norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
    Indications
    Contact with health services for contraceptive management
  311. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 125 mg
    • Oral > Solid > tablet: 250 mg
    Indications
    Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis
  312. Ethosuximide General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
    Indications
    Absence seizures, typical
  313. Etonogestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
    Indications
    Contact with health services for insertion of contraceptive device
  314. Etoposide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
    • Oral > Solid: 100 mg capsule
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Retinoblastoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  315. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  316. Exenatide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity
  317. Fentanyl General information
    Section
    Opioid analgesics
    • Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
    • Oral > Other: 200 to 1200 µg buccal film (as citrate)
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
    Indications
    Other specified chronic cancer related pain Chronic cancer pain
  318. Ferrous salt General information
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
    • Oral > Solid > tablet: 60 to 65 mg elemental iron
    Indications
    Iron deficiency anaemia
  319. Ferrous salt + folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 60 mg iron + 2.8 mg
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
    Indications
    Iron deficiency anaemia Iron deficiency anaemia Spina bifida Clefts of lip, alveolus or palate Anencephaly or similar anomalies
  320. Fexinidazole General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid > tablet: 600 mg
    • Oral > Solid: 600 mg
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 600 mg
    • Oral > Solid: 600 mg
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
  321. Fexofenadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type
  322. Fifth generation cephalosporins General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  323. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  324. Fingolimod General information
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid: 0.25 mg; 0.5 mg
    Indications
    Relapsing-remitting multiple sclerosis
  325. Flomoxef General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales
  326. Flucloxacillin General information
    Section
    Access group antibiotics
    Indications
    First choice
    Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Therapeutic equivalent to cloxacillin for Sepsis without septic shock
  327. Fluconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
    • Oral > Solid > capsule: 50 mg
    Indications
    Cryptococcosis Candidosis
  328. Flucytosine General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
    Cryptococcosis
  329. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  330. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Liquid: 100 µg per mL
    • Oral > Solid > tablet: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  331. Fluorescein General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
    Fluorescein
  332. Fluoride General information
    Section
    Dental medicines and preparations
    • Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
    • Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
    • Local > Dental > Varnish: 22500 ppm fluoride (any type)
    Indications
    Dental caries
  333. Fluorouracil General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
    Plantar warts
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per mL in vial
    • Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
    Indications
    Malignant neoplasms of nasopharynx Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites
  334. Fluoxetine General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Palliative care
    Section
    Medicines for depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Depressive disorders
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Generalised anxiety disorder Social anxiety disorder Panic disorder
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Obsessive-compulsive disorder
  335. Fluphenazine General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
    Indications
    Schizophrenia or other primary psychotic disorders
  336. Flutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  337. Fluticasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  338. Fluticasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  339. Fluticasone furoate + vilanterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  340. Fluvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  341. Fluvoxamine General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
  342. Folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 400 µg
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    Indications
    Cephalocele Anencephaly or similar anomalies Spina bifida Folate deficiency anaemia
  343. Fomepizole General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  344. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales
  345. Fourth generation cephalosporins General information
    Section
    Watch group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  346. Fremanezumab General information
    Section
    Medicines for migraine prophylaxis
    • Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe
    Indications
    Chronic migraine
  347. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  348. Fulvestrant General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 250 mg per 5 mL
    Indications
    Malignant neoplasms of breast
  349. Furosemide General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Anuria or oliguria Oedema
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Heart failure
  350. Gabapentin General information
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg
    Indications
    Neuropathic pain
  351. Galcanezumab General information
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab for Chronic migraine
  352. Gallamine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)
    Indications
    Muscle relaxants
  353. Gatifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  354. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  355. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  356. Gentamicin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Other specified prophylactic measures Gonococcal infection
    Other indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
    Indications
    Other specified conjunctivitis Infectious blepharitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neonatal meningitis
  357. Glass ionomer cement General information
    Section
    Dental medicines and preparations
    • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
    Indications
    Dental caries
  358. Glatiramer acetate General information
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
    • Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
    Indications
    Relapsing-remitting multiple sclerosis Multiple sclerosis
  359. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 20 mg granules
    • Oral > Solid > tablet: 100 mg + 40 mg
    Indications
    Chronic hepatitis C
  360. Glibenclamide General information
    Section
    Hypoglycaemic agents
    • Oral > Solid: 5 mg; 2.5 mg
    Indications
    Type 2 diabetes mellitus
  361. Gliclazide General information
    Section
    Hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  362. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent
    Indications
    Hypoglycaemia in the context of diabetes
  363. Glucose General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 50% hypertonic
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    Indications
    Hypoglycaemia without associated diabetes Other specified disorders of fluid, electrolyte or acid-base balance
  364. Glucose + sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  365. Glutaral General information
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
    Indications
    Glutaral nonmedicinal
  366. Glycerol General information
    Section
    Dermatological medicines > Moisturizers
    • Local > Topical > Cream: 15 to 20%
    Indications
    Atopic eczema
  367. Glyceryl trinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
    Angina pectoris
  368. Glycopyrronium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  369. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  370. Goserelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  371. Granisetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  372. Griseofulvin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
    Dermatophytosis
  373. Haemophilus influenzae type b vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  374. Haloperidol General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Palliative care
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Solid: 2 mg; 5 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  375. Haloperidol decanoate General information
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders
  376. Halothane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  377. Heparin sodium General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  378. Hepatitis A vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  379. Hepatitis B vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  380. Hepatitis E vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  381. Homatropine General information
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
    Indications
    Anterior uveitis Therapeutic equivalent to atropine for Anterior uveitis
  382. Human papilloma virus (HPV) vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  383. Hydralazine General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Essential hypertension Gestational hypertension
  384. Hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Indications
    Essential hypertension
    Section
    Diuretics
    • Oral > Solid > dosage form: 25 mg; 12.5 mg
    Indications
    Oedema
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Heart failure
  385. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of unspecified sites
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Ointment: 1% (acetate)
    Indications
    Scleritis Anterior uveitis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Anaphylaxis
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema: 100 mg per 60 mL
    Indications
    Crohn disease site Ulcerative colitis
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
    Indications
    Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
    • Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule
    Indications
    Adrenocortical insufficiency
  386. Hydromorphone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  387. Hydroxocobalamin General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  388. Hydroxychloroquine General information
    Section
    Antimalarial medicines > Medicines for chemoprevention
    Indications
    Therapeutic equivalent to chloroquine for Malaria due to Plasmodium falciparum
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
    Indications
    Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type
  389. Hydroxyurea (hydroxycarbamide) General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
    Section
    Medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
  390. Hyoscine butylbromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
    Palliative care
  391. Hyoscine hydrobromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
    Palliative care
  392. Hypochlorous acid General information
    Section
    Disinfectants
    • Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million
    Indications
    Disinfectant, not elsewhere classified
    Section
    Antiseptics
    • Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million
    Indications
    Hypochlorite
  393. Hypromellose General information
    Section
    Ophthalmological preparations
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Keratoconjunctivitis sicca
  394. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  395. Ibuprofen General information
    Section
    Medicines for acute migraine attacks
    • Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg
    Indications
    Migraine
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Indications
    Patent arterial duct
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
    Indications
    Pain
  396. Idoxuridine General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.1%
    • Local > Ophthalmological > Ointment: 0.2%
    Indications
    Herpes simplex keratitis
  399. Imipenem + cilastatin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
    Indications
    Second choice
    Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Neutropaenia (high-risk) Therapeutic equivalent to meropenem for Peritonitis (severe)
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis
  400. Imipenem + cilastatin + relebactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
    • Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales
  401. Indapamide General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  402. Indinavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 400 mg (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  403. Indometacin General information
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen for Patent arterial duct
  404. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab for Psoriasis of unspecified type
  405. Influenza vaccine (seasonal) General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  406. Insulin (analogue, long-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  407. Insulin (analogue, rapid-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  408. Insulin (human, intermediate-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  409. Insulin (human, short-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  410. Insulin analogues General information
    Section
    Insulins
    • Not specified
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  411. Insulin aspart General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  412. Insulin degludec General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  413. Insulin detemir General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  414. Insulin glargine General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  415. Insulin glulisine General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  416. Insulin lispro General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  417. Intraperitoneal dialysis solution General information
    Section
    Peritoneal dialysis solution
    • Solution: of appropriate composition in accordance with local clinical guidelines.
    Indications
    Care involving peritoneal dialysis
  418. Iodine General information
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to povidone iodine for Povidone iodine
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)
    Indications
    Iodine deficiency
  419. Iodine + potassium iodide (Lugol's solution) General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 5% w/v + 10% w/v (aqueous)
    Indications
    Thyrotoxicosis
  420. Iohexol General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
    Indications
    X-ray contrast media, iodinated
  421. Ipecacuanha General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  422. Ipilimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion
    Indications
    Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin Other specified malignant neoplasms of bronchus or lung
  423. Ipratropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler
    Indications
    Chronic obstructive pulmonary disease Asthma
  424. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Rhabdomyosarcoma primary site Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis
  425. Isoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  426. Isoniazid General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 100 mg per mL
    • Oral > Solid > dispersible tablet: 100 mg (scored)
    • Oral > Solid > tablet: 100 mg; 300 mg
    Indications
    Other specified tuberculosis Tuberculosis
  427. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
    Indications
    Tuberculosis
  428. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
    Indications
    Other specified prophylactic measures
  429. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 75 mg
    • Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
    Indications
    Tuberculosis
  430. Isoniazid + rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  431. Isoprenaline General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
    • Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)
    Indications
    Bradycardia Cardiogenic shock
  432. Isosorbide dinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
    Angina pectoris
  434. Ivacaftor General information
    Section
    Medicines for cystic fibrosis
    • Oral > Solid > tablet: 75 mg; 150 mg
    • Oral > Solid > granules: 59.5 mg; 75 mg
    Indications
    Cystic fibrosis
  435. Ivermectin General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 3 mg
    Indications
    Hookworm diseases Strongyloidiasis Trichuriasis Ancylostomiasis Ascariasis
    Section
    Antifilarials
    • Oral > Solid > tablet: 3 mg
    Indications
    Lymphatic filariasis Onchocerciasis
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid > tablet: 3 mg
    Indications
    Scabies
  436. Kanamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  437. Kanamycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  438. Ketamine General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride)
    Indications
    Anaesthetics and therapeutic gases
  439. Ketoconazole General information
    Section
    Medicines for endocrine disorders
    • Oral > Solid > tablet: 200 mg
    Indications
    Cushing syndrome
  440. Lactulose General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.3 to 3.4 g per 5 mL oral liquid
    Indications
    Palliative care
  441. Lamivudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  442. Lamivudine + nevirapine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  444. Lamivudine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  445. Lamotrigine General information
    Section
    Antiseizure medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
    Indications
    Epilepsy or seizures
  446. Latanoprost General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
    Indications
    Primary open-angle glaucoma
  447. Ledipasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  448. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  449. Lenvatinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 4 mg; 10 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  450. Letrozole General information
    Section
    Ovulation inducers
    • Oral > Solid > dosage form: 2.5 mg
    Indications
    Female infertility without specification whether primary or secondary
  451. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  452. Levamisole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
    Indications
    Ascariasis
  453. Levetiracetam General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
    • Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
    Indications
    Epilepsy or seizures Status epilepticus
  454. Levodopa General information
    Section
    Medicines for parkinsonism
    • Oral > Solid: 250 mg
    Indications
    Parkinson disease
  455. Levodopa + benserazide General information
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to levodopa + carbidopa for Parkinson disease
  456. Levodopa + carbidopa General information
    Section
    Medicines for parkinsonism
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
    Indications
    Parkinson disease
  457. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  458. Levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
    Indications
    Contact with health services for insertion of contraceptive device
  459. Levonorgestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
    Indications
    Contact with health services for insertion of contraceptive device
  460. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  461. Lidocaine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Indications
    Ventricular tachyarrhythmia
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
    Indications
    Local anaesthetics
  462. Lidocaine + epinephrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
    Indications
    Local anaesthetics
  463. Lindane General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Cream: 1%
    • Local > Topical > Lotion: 1%
    Indications
    Scabies
  464. Linezolid General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg (scored)
    • Oral > Solid > tablet: 600 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  465. Liraglutide General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen
    Indications
    Obesity
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  466. Lisinopril + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
    Indications
    Essential hypertension
  467. Lisinopril + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
    Indications
    Essential hypertension
  468. Lisocabtagene maraleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  469. Lithium carbonate General information
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 300 mg
    Indications
    Bipolar or related disorders
  470. Loperamide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid > dosage form: 2 mg
    Indications
    Palliative care
  471. Lopinavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
    • Oral > Solid > dosage form: 40 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  472. Loratadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
  473. Lorazepam General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
    Indications
    Status epilepticus
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to diazepam for Anxiety
  474. Losartan General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Heart failure
  475. Lovastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  476. Magnesium sulfate General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
    Indications
    Severe pre-eclampsia Eclampsia
  477. Malaria vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain specified single infectious diseases
  478. Mannitol General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
    Indications
    Ocular hypertension Cerebral oedema
  479. Measles vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  480. Mebendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Hookworm diseases Trichuriasis Ascariasis Enterobiasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Other specified echinococcosis
  481. Medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Indications
    Contact with health services for reasons associated with reproduction
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  482. Mefloquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  483. Meglumine antimoniate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  484. Meglumine iotroxate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
    Indications
    X-ray contrast media, iodinated
  485. Melarsoprol General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
    Indications
    Gambiense trypanosomiasis Rhodesiense trypanosomiasis
  486. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  487. Meningococcal meningitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  489. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Neonatal meningitis Peritoneal abscess (severe) Neutropaenia (high-risk) Peritonitis (severe)
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Neonatal meningitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  491. Mesalazine General information
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine for Crohn disease site Therapeutic equivalent to sulfasalazine for Ulcerative colitis
  492. Mesna General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
    • Oral > Solid > tablet: 400 mg; 600 mg
    • Oral > Other: 600 mg
    • Oral > Solid > tablet: 400 mg
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
    • Oral > Solid: 400 mg; 600 mg
    Indications
    Rhabdomyosarcoma primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Osteosarcoma of bone or articular cartilage of unspecified sites Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia
  493. Metformin General information
    Section
    Hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  494. Methadone General information
    Section
    Medicines for opioid use disorders
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Indications
    Opioid dependence
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    • Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
    Indications
    Chronic cancer pain
  495. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 5 mg; 10 mg
    Indications
    Thyrotoxicosis
  496. Methionine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg (DL)
    Indications
    Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  497. Methotrexate General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
    • Oral > Solid: 2.5 mg (as sodium salt)
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
    Indications
    Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
    Indications
    Psoriasis of unspecified type
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: pre-filled syringe in multiple strengths
    Indications
    Crohn disease site Psoriatic arthritis
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Juvenile idiopathic arthritis
  498. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  499. Methyldopa General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
    Indications
    Essential hypertension Gestational hypertension
  500. Methylergometrine General information
    Section
    Uterotonics
    Indications
    Therapeutic equivalent to ergometrine for Postpartum haemorrhage
  501. Methylphenidate General information
    Section
    Medicines for mental and behavioural disorders
    • Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride)
    • Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)
    Indications
    Attention deficit hyperactivity disorder
  502. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified
  503. Methylthioninium chloride General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
    Indications
    Acquired methaemoglobinaemia
  504. Meticillin General information
    Section
    Access group antibiotics
    Indications
    First choice
    Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Therapeutic equivalent to cloxacillin for Sepsis without septic shock
  505. Metoclopramide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (scored) (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Nausea or vomiting
  506. Metoprolol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
  507. Metronidazole General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    Amoebiasis
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Local > Rectal > Suppository: 500 mg; 1 g
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    Indications
    First choice
    Trichomoniasis Intestinal infections due to Clostridioides difficile Necrotising fasciitis co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe)
    Second choice
    co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate)
    Other indications
    Bacterial infection of unspecified site
  508. Micafungin General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
    Indications
    Systemic or invasive candidosis
  509. Miconazole General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
    Indications
    Fungal infection of the skin
  510. Midazolam General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    Indications
    Therapeutic equivalent to lorazepam for Status epilepticus Status epilepticus
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
    • Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    • Oral > Solid > dosage form: 7.5 mg; 15 mg
    Indications
    Palliative care
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL in 5 vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid > dosage form: 15 mg; 7.5 mg
    Indications
    Sedative-hypnotic and anxiolytic drugs
  511. Mifepristone - misoprostol General information
    Section
    Medicines for medical abortion
    • Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
    Indications
    Unspecified time of fetal death, cause not specified Induced abortion
  512. Miltefosine General information
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
    Indications
    Visceral leishmaniasis Cutaneous leishmaniasis Mucocutaneous leishmaniasis
  513. Misoprostol General information
    Section
    Uterotonics
    • Local > Vaginal > tablet: 25 µg
    • Oral > Solid: 200 µg
    Indications
    Unspecified obstetric condition Postpartum haemorrhage
    Section
    Medicines for medical abortion
    • Oral > Solid > tablet: 200 µg
    Indications
    Spontaneous abortion, incomplete, without complication
  514. Mometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  515. Mometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  516. Morphine General information
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (morphine hydrochloride or morphine sulfate); 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    • Oral > Solid > tablet: 10 mg immediate release (morphine sulfate)
    • Oral > Solid > dosage form: 30 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 5 mg slow-release (morphine hydrochloride or morphine sulfate)
    • Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)
    Indications
    Pain
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
    Opioids or related analgesics and agents affecting opioid receptors
  517. Moxidectin General information
    Section
    Antifilarials
    • Oral > Solid > tablet: 2 mg
    Indications
    Therapeutic equivalent to ivermectin for Lymphatic filariasis Therapeutic equivalent to ivermectin for Onchocerciasis
  518. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculosis
  519. Mpox vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  520. Multiple micronutrient powder General information
    Section
    Vitamins and minerals
    • Sachets containing:
    • - iron (elemental) 12.5 mg (as coated ferrous fumarate)
    • - zinc (elemental) 5 mg
    • - vitamin A 300 micrograms
    • - with or without other micronutrients at recommended daily values
    Indications
    Iron deficiency anaemia
  521. Multiple micronutrient supplement General information
    Section
    Other medicines administered to the mother
    • Tablet containing:
    • Vit A: 800 mcg retinol activity equivalent
    • Vit C: 70 mg
    • Vit D: 5 mcg (200 IU)
    • Vit E: 10 mg alpha tocopherol equivalent
    • Vit B1: 1.4 mg
    • Vit B2: 1.4 mg
    • Vit B3: 18 mg niacin equivalent
    • Vit B6: 1.9 mg
    • Folic acid: 400 mcg
    • Vit B12: 2.6 mcg
    • Iron: 30 mg
    • Iodine: 150 mcg
    • Zinc: 15 mg
    • Selenium: 65 mcg
    • Copper: 2 mg
    Indications
    Maternal care for other specified conditions predominantly related to pregnancy
  522. Mumps vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  523. Mupirocin General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
    Indications
    Superficial bacterial folliculitis Impetigo
  524. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  525. Nafcillin General information
    Section
    Access group antibiotics
    Indications
    First choice
    Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Therapeutic equivalent to cloxacillin for Sepsis without septic shock
  526. Nalidixic acid General information
    Section
    Anti-infective medicines
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Shigella resistant to unspecified antibiotic
  527. Naloxone General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
    Indications
    Unintentional exposure to or harmful effects of opioids or related analgesics
  528. Naltrexone General information
    Section
    Medicines for alcohol use disorders
    • Parenteral > General injections > IM: 380 mg in vial (extended-release)
    • Oral > Solid > tablet: 50 mg
    Indications
    Disorders due to use of alcohol
  529. Naproxen General information
    Section
    Medicines for acute migraine attacks
    Indications
    Therapeutic equivalent to ibuprofen for Migraine
  530. Natamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
    Indications
    Infectious keratitis
  531. Nelfinavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 250 mg (as mesilate)
    • Oral > Other: 50 mg per g oral powder
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  532. Neostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    • Oral > Solid > tablet: 15 mg (neostigmine bromide)
    Indications
    Anticholinesterase reversible Myasthenia gravis
    Section
    Medicines for myasthenia gravis
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    • Oral > Solid > tablet: 15 mg (neostigmine bromide)
    Indications
    Myasthenia gravis
  533. Netilmicin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  534. Nevirapine General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > dispersible tablet: 50 mg
    • Oral > Solid > tablet: 200 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  535. Niclosamide General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
    Indications
    Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium
  536. Nicotinamide General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Pellagra
  537. Nicotine replacement therapy General information
    Section
    Medicines for nicotine use disorders
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
    • Oral > Solid > lozenge: 2 mg; 4 mg lozenge
    • Local > Buccal > Oral spray: 1 mg per actuation
    • Local > Buccal > Chewing gum: 2 mg; 4 mg
    Indications
    Nicotine dependence
  538. Nifedipine General information
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
    Indications
    Preterm labour without delivery
    Section
    Antianginal medicines
    • Oral > Solid: 10 mg
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg tablet; sustained-release formulations
    Indications
    Essential hypertension
  539. Nifurtimox General information
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Chagas disease
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Gambiense trypanosomiasis
  540. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myelogenous leukaemia, BCR-ABL1-positive
  541. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  542. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    First choice
    Infectious cystitis
  543. Nitrous oxide General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  544. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Melanoma of skin Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung
  545. Norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 350 µg
    Indications
    Contact with health services for contraceptive management
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle
  546. Norethisterone enantate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
    Indications
    Contact with health services for reasons associated with reproduction
  547. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis
    Section
    Medicines for Guillain-Barré syndrome
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    Indications
    Acute inflammatory demyelinating polyneuropathy
  548. Nystatin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL
    • Local > Topical > Other: 100000 IU pessary
    • Oral > Solid > dosage form: 500000 IU
    • Oral > Solid > lozenge: 100000 IU
    Indications
    Candidosis
  549. Ocrelizumab General information
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
    • Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution
    Indications
    Relapsing-remitting multiple sclerosis Multiple sclerosis
  550. Octreotide General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
    Indications
    Acromegaly or pituitary gigantism
  551. Ofloxacin General information
    Section
    Ear, nose and throat medicines [c]
    Indications
    Therapeutic equivalent to ciprofloxacin for Infectious diseases of external ear
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Other specified conjunctivitis Infectious keratitis
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  552. Olanzapine General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 10 mg in vial powder for injection
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  553. Omadacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 100 mg lyophilized powder for injection
    • Oral > Solid: 300 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  554. Ombitasvir + paritaprevir + ritonavir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  555. Omeprazole General information
    Section
    Antiulcer medicines
    • Parenteral > General injections > IV: 40 mg in vial
    • Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid
    • Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg
    Indications
    Gastrointestinal bleeding Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  556. Ondansetron General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)
    • Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
    • Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule
    • Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
    • Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)
    Indications
    Nausea or vomiting
  557. Oral rehydration salts General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq or mmol/L
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mEq or mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq or mmol/L
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mEq or mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Diarrhoea
  558. Oral rehydration salts - zinc sulfate General information
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)
    Indications
    Diarrhoea
  559. Oseltamivir General information
    Section
    Other antivirals
    • Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
    Indications
    Influenza due to identified seasonal influenza virus
  560. Osimertinib General information
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
    Indications
    Other specified malignant neoplasms of bronchus or lung
  561. Oxacillin General information
    Section
    Access group antibiotics
    Indications
    First choice
    Therapeutic equivalent to cloxacillin for Bacterial infection of joint Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Therapeutic equivalent to cloxacillin for Sepsis without septic shock
  562. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  563. Oxamniquine General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid > capsule: 250 mg
    Indications
    Schistosomiasis due to Schistosoma mansoni
  564. Oxazolindinones General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  565. Oxycodone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  566. Oxygen General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Indications
    Anaesthetics and therapeutic gases
    Section
    Medical gases
    • Respiratory > Inhalation:
    Indications
    Respiratory failure as acute or chronic
  567. Oxytetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma
  568. Oxytocin General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
    Indications
    Postpartum haemorrhage
  569. P-aminosalicylate sodium General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  570. P-aminosalicylic acid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 4 g granules in sachet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  572. Palbociclib General information
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
    Indications
    Other specified malignant neoplasms of breast
  573. Paliperidone General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  574. Palonosetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  575. Pancreatic enzymes General information
    Section
    Gastrointestinal medicines
    • Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.
    • *Units expressed in Ph. Eur
    Indications
    Enzyme intestinal
    Section
    Medicines for cystic fibrosis
    • Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.
    • *Units expressed in Ph. Eur
    Indications
    Cystic fibrosis
  576. Panitumumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial
    Indications
    Other specified malignant neoplasms of large intestine
  577. Paracetamol (acetaminophen) General information
    Section
    Medicines for acute migraine attacks
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Migraine
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 100 mg; 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Pain
  578. Paromomycin General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
    Indications
    Visceral leishmaniasis
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 125 mg per 5 mL as sulfate
    • Oral > Solid: 250 mg as sulfate
    Indications
    Amoebiasis
  579. Paroxetine General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
  580. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  581. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  582. Pegylated interferon alfa (2a) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  583. Pegylated interferon alfa (2b) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  584. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    Indications
    Melanoma of skin Other specified malignant neoplasms of large intestine Malignant neoplasms of cervix uteri Adenocarcinoma of stomach Malignant neoplasms of oesophagogastric junction Squamous cell carcinoma of hypopharynx and variants Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Squamous cell carcinoma of nasopharynx Therapeutic equivalent to nivolumab for Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Carcinoma of breast, specialised type Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung
  585. Penicillamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
    Indications
    Rheumatoid arthritis, serology unspecified
  586. Pentamidine General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)
    Indications
    Visceral leishmaniasis
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
    Indications
    Gambiense trypanosomiasis
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)
    Indications
    Pneumocystosis
  587. Perindopril + amlodipine + indapamide General information
    Section
    Antihypertensive medicines
    • Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg
    Indications
    Essential hypertension
  588. Permethrin General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
    Indications
    Pediculosis corporis Pediculosis capitis Scabies
  589. Pertussis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  590. Pertuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
    Indications
    Carcinoma of breast, specialised type
  591. Phenelzine General information
    Section
    Medicines for depressive disorders
    • Oral > Solid > dosage form: 15 mg (as sulfate)
    Indications
    Other specified depressive disorders
  592. Phenobarbital General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg
    Indications
    Status epilepticus Epilepsy or seizures
  593. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    • Oral > Solid: 250 mg (as potassium salt) tablet
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Periapical abscess without sinus Acute pharyngitis
    Other indications
    Bacterial infection of unspecified site
  594. Phenytoin General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 30 mg per 5 mL (phenytoin)
    • Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
    • Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
    • Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)
    Indications
    Epilepsy or seizures
  595. Phosphorus General information
    Section
    Medicines for endocrine disorders
    • Oral > Other: 500 mg in sachet (elemental phosphorus) granules
    • Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)
    Indications
    Hypophosphataemic rickets
  596. Phytomenadione General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution; 1 mg per 0.5 mL in ampoule
    • Oral > Solid > tablet: 5 mg tablet
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors Haemorrhagic or haematological disorders of fetus or newborn
  597. Pilocarpine General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
    Indications
    Acute angle closure with pupillary block Ocular hypertension Primary open-angle glaucoma
  598. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    First choice
    Other specified pneumonia (Hospital-acquired pneumonia) Neutropaenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) co-prescribed with clindamycin Necrotising fasciitis
  599. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  601. Pneumococcal vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  602. Podophyllotoxin General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin for Plantar warts Therapeutic equivalent to podophyllum resin for Anogenital warts
  603. Podophyllum resin General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
    Indications
    Plantar warts Anogenital warts
  604. Poliomyelitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  605. Polygeline General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    • Parenteral > General injections > IV: 3.5% in solution
    Indications
    Therapeutic equivalent to dextran 70 for Hypovolaemia Hypovolaemia
  606. Polymyxin B (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli
  607. Polymyxins General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  608. Porcatant alfa General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  609. Potassium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
    Hypokalaemia
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
    Hypokalaemia
  610. Potassium ferric hexacyanoferrate (Prussian blue) General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  611. Potassium iodide General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 65 mg (scored)
    Indications
    Thyrotoxicosis
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Sporotrichosis
  612. Potassium permanganate General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
    Indications
    Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin or subcutaneous tissue Impetigo
  613. Povidone iodine General information
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
    Povidone iodine
  614. Pralidoxime General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • .
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
  615. Pramipexole General information
    Section
    Medicines for central nervous system disorders
    • Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release
    Indications
    Parkinson disease
  616. Pravastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  617. Praziquantel General information
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Cysticercosis of central nervous system
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Diphyllobothriasis Taeniasis due to Taenia saginata Hymenolepiasis Taeniasis due to Taenia solium
  618. Precipitated sulfur General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Ointment:
    Indications
    Therapeutic equivalent to benzyl benzoate for Pediculosis corporis Therapeutic equivalent to benzyl benzoate for Pediculosis capitis Therapeutic equivalent to benzyl benzoate for Pthiriasis Therapeutic equivalent to benzyl benzoate for Scabies
  619. Prednisolone General information
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Retention enema:
    • Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
    Indications
    Therapeutic equivalent to hydrocortisone for Crohn disease site Crohn disease site Ulcerative colitis
    Section
    Hormones and antihormones
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant neoplasms of prostate Follicular lymphoma
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
    Indications
    Scleritis Anterior uveitis
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Adrenocortical insufficiency
    Section
    Medicines for cluster headache
    • Oral > Solid > tablet: 5 mg; 25 mg
    Indications
    Trigeminal autonomic cephalalgias
    Section
    Antiseizure medicines
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid > tablet: 1 mg; 5 mg; 10 mg
    Indications
    Infantile spasms
  620. Prednisone General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphoma, not otherwise specified Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Follicular lymphoma
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to prednisolone for Allergic or hypersensitivity conditions of unspecified type
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Therapeutic equivalent to prednisolone for Adrenocortical insufficiency
  621. Pretomanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  622. Primaquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  623. Probenecid General information
    Section
    Medicines used to treat gout
    • Oral > Solid: 500 mg
    Indications
    Gout
  624. Procainamide General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)
    • Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  625. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    First choice
    Congenital syphilis [children]
    Second choice
    Syphilis
  626. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma
  627. Progesterone vaginal ring General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
    Indications
    Contact with health services for contraceptive management
  628. Proguanil General information
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid: 100 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  629. Promethazine General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL (hydrochloride)
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule
    Indications
    Nausea or vomiting
  630. Propanol General information
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to ethanol for Denatured alcohol
  631. Propofol General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
    Indications
    Anaesthetics and therapeutic gases
  632. Propranolol General information
    Section
    Antianginal medicines
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
    • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Essential hypertension
    Section
    Medicines for migraine prophylaxis
    • Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)
    Indications
    Migraine
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
    • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Cardiac arrhythmia
  633. Propylthiouracil General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  634. Protamine sulfate General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors
  635. Protionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 250 mg (scored)
    Indications
    Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis
  636. Pyrantel General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
    Indications
    Hookworm diseases Trichuriasis Ascariasis Enterobiasis
  637. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 400 mg; 500 mg
    Indications
    Tuberculosis
  638. Pyridostigmine General information
    Section
    Medicines for myasthenia gravis
    • Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
    • Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)
    Indications
    Myasthenia gravis
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
    • Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)
    Indications
    Myasthenia gravis
  639. Pyridoxine General information
    Section
    Vitamins and minerals
    • Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride)
    Indications
    Other specified polyneuropathy Vitamin B6 deficiency Sideroblastic anaemia
  640. Pyrimethamine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
    Toxoplasmosis
  641. Quetiapine General information
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
    Indications
    Bipolar or related disorders
  642. Quinidine General information
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 200 mg (sulfate)
    Indications
    Cardiac arrhythmia
  643. Quinine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion
    Indications
    Malaria due to Plasmodium falciparum
  644. Rabies vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  645. Raltegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Liquid: 100 mg granules for oral suspension
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  646. Ranibizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • .
    Indications
    Retinal venous occlusions Diabetic macular oedema Degenerative high myopia Age-related macular degeneration
  647. Ranitidine General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
    Indications
    Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  648. Rasburicase General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution
    Indications
    Tumour lysis syndrome
  649. Ravidasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
    Indications
    Chronic hepatitis C
  650. Ready to use therapeutic food General information
    Section
    Therapeutic foods
    • Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.
    Indications
    Acute malnutrition in infants, children or adolescents
  651. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  652. Red blood cells General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  653. Resin-based composite (high-viscosity) General information
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use capsule or multi-use syringe
    Indications
    Dental caries
  654. Resin-based composite (low-viscosity) General information
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use applicator or multi-use bottle
    Indications
    Dental caries
  655. Respiratory syncytial virus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  656. Retinol General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate)
    • Oral > Liquid: 100000 IU per mL (as palmitate or acetate)
    • Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule
    Indications
    Vitamin A deficiency
  657. Ribavirin General information
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Viral haemorrhagic fever, not elsewhere classified
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
  658. Ribociclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  659. Riboflavin General information
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
    Indications
    Vitamin B2 deficiency
  660. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  661. Rifampicin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 600 mg in vial powder for injection
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Other specified tuberculosis Tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  662. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 150 mg; 300 mg
    Indications
    Latent tuberculosis Tuberculosis
  663. Risdiplam General information
    Section
    Medicines for neurological disorders
    • Oral > Liquid: 0.75 mg per mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 5 mg
    Indications
    Spinal muscular atrophy
  664. Risperidone General information
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
    • Parenteral > General injections > IM:
    Indications
    Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone for Schizophrenia or other primary psychotic disorders
  665. Ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  666. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia Follicular lymphoma
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  667. Rivaroxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Other specified atrial fibrillation Therapeutic equivalent to dabigatran for Venous thromboembolism
  668. Ropinirole General information
    Section
    Medicines for central nervous system disorders
    • Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release
    Indications
    Parkinson disease
  669. Rotavirus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  670. Rubella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  671. Salbutamol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers
    Indications
    Chronic obstructive pulmonary disease Asthma
  672. Salicylic acid General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses
  673. Saquinavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 200 mg; 500 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  674. Selenium sulfide General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
    Indications
    Seborrhoeic dermatitis Pityriasis versicolor
  675. Semaglutide General information
    Section
    Hypoglycaemic agents
    • Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution
    • Oral > Solid > tablet: 3 mg
    • Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL
    Indications
    Obesity Type 2 diabetes mellitus
  676. Senna General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Palliative care
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
    Constipation
  677. Sertraline General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
  678. Sevoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  679. Silver diamine fluoride General information
    Section
    Dental medicines and preparations
    • Local > Dental > Solution: 38% w/v
    Indications
    Dental caries
  680. Silver nitrate General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1%
    Indications
    Neonatal conjunctivitis or dacryocystitis
  681. Silver sulfadiazine General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
    Burns
  682. Simeprevir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 150 mg
    Indications
    Chronic hepatitis C
  683. Simvastatin General information
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
    Indications
    Mixed hyperlipidaemia Coronary atherosclerosis
    Section
    Medicines for endocrine disorders
    • Oral > Solid: 20 mg
    Indications
    Polycystic ovary syndrome
  684. Smallpox vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  685. Snake antivenom General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • .
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  686. Sodium calcium edetate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  687. Sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  688. Sodium hyaluronate General information
    Section
    Ophthalmological preparations
    Indications
    Therapeutic equivalent to hypromellose for Keratoconjunctivitis sicca
  689. Sodium hydrogen carbonate General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
    Acidosis
  690. Sodium nitrite General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  691. Sodium nitroprusside General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
    Indications
    Hypertensive crisis
  692. Sodium stibogluconate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  693. Sodium thiosulfate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 15%
    Indications
    Pityriasis versicolor
  694. Sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg; 400 mg
    • Oral > Solid > granules: 200 mg in sachet
    Indications
    Chronic hepatitis C
  695. Sofosbuvir + velpatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
    • Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet
    Indications
    Chronic hepatitis C
  696. Somatropin General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge
    Indications
    Hypoglycaemia without associated diabetes
  697. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choice
    Gonococcal infection
    Other indications
    Bacterial infection of unspecified site
  698. Spironolactone General information
    Section
    Diuretics
    • Oral > Liquid: 25 mg per 5 mL
    • Oral > Solid > tablet: 25 mg; 12.5 mg
    Indications
    Oedema Ascites
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 25 mg
    Indications
    Heart failure
  699. Stavudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 5 mg per 5 mL powder for oral solution
    • Oral > Solid: 15 mg; 20 mg; 30 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  700. Streptokinase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
    Indications
    Acute myocardial infarction
  701. Streptomycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  702. Succimer General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  703. Sulfacetamide General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 10% (sodium salt)
    Indications
    Other specified conjunctivitis
  704. Sulfadiazine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
    Toxoplasmosis
    Section
    Anti-infective medicines
    • Oral > Solid: 500 mg
    • Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)
    Indications
    Bacterial infection of unspecified site
  705. Sulfadimidine General information
    Section
    Anti-infective medicines
    • Oral > Liquid: 500 mg per 5 mL
    • Oral > Solid: 500 mg
    • Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)
    Indications
    Bacterial infection of unspecified site
  706. Sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    • Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 500 mg + 25 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  707. Sulfamethoxazole + trimethoprim General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Pneumocystosis
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    Indications
    First choice
    Infectious cystitis
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent
    Other indications
    Bacterial infection of unspecified site
  708. Sulfasalazine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 500 mg
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema: 3 g per 100 mL
    Indications
    Crohn disease site Ulcerative colitis
  709. Sumatriptan General information
    Section
    Medicines for cluster headache
    • Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe
    Indications
    Trigeminal autonomic cephalalgias
    Section
    Medicines for acute migraine attacks
    • Oral > Solid > tablet: 50 mg
    Indications
    Migraine
  710. Sunscreen, broad-spectrum General information
    Section
    Dermatological medicines
    • Topical cream, lotion, gel, ointment, spray with sun protection factor ≥ 50.
    Indications
    Xeroderma pigmentosum
    Section
    Dermatological medicines > Sunscreens
    • Topical:
    • Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).
    Indications
    Albinism or other specified genetically-determined hypomelanotic disorders
  711. Suramin sodium General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    Rhodesiense trypanosomiasis
    Section
    Antifilarials
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    Filariasis
  712. Suxamethonium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)
    Indications
    Muscle relaxants
  713. Tacalcitol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type
  714. Tacrolimus General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
    Indications
    Failure or rejection of transplanted organs or tissues
  715. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
  716. Tedizolid General information
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus
  717. Telmisartan + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
    Indications
    Essential hypertension
  718. Telmisartan + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
    Indications
    Essential hypertension
  719. Temozolomide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    • Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg
    Indications
    Other specified gliomas of brain Neuroblastoma, NOS Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites
  720. Tenofovir alafenamide General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 25 mg
    Indications
    Chronic hepatitis B
  721. Tenofovir disoproxil fumarate General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Contact with or exposure to human immunodeficiency virus Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B
  722. Terbinafine General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
    Indications
    Fungal infection of the skin
  723. Terbutaline General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to salbutamol for Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol for Asthma
  724. Terizidone General information
    Section
    Antituberculosis medicines
    • Oral > Solid > capsule: 250 mg
    Indications
    Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis
  725. Testosterone General information
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  726. Tetanus antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 50000 IU in vial
    Indications
    Tetanus
  727. Tetanus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  728. Tetracaine General information
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  729. Tetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
    Indications
    Neonatal conjunctivitis or dacryocystitis Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma
    Section
    Access group antibiotics
    • Oral > Solid: 250 mg (hydrochloride)
    Indications
    Bacterial infection of unspecified site
  730. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  731. Thiamine General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride)
    • Oral > Solid > tablet: 50 mg (hydrochloride)
    Indications
    Vitamin B1 deficiency
  732. Thiopental General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    Indications
    Therapeutic equivalent to propofol for Anaesthetics and therapeutic gases
  733. Ticagrelor General information
    Section
    Anti-platelet medicines
    • Oral > Solid > tablet: 60 mg; 90 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  734. Tick-borne encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  735. Tigecycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  736. Timolol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
    Indications
    Ocular hypertension Primary open-angle glaucoma
  737. Tinidazole General information
    Section
    Antiamoebic and antigiardiasis medicines
    Indications
    Therapeutic equivalent to metronidazole for Amoebiasis
  738. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  739. Tiotropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 18 µg in capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler
    Indications
    Chronic obstructive pulmonary disease
  740. Tirzepatide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  741. Tisagenlecleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  742. Tislelizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 10 mL
    • Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
    • Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion
    Indications
    Malignant neoplasms of urinary tract Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung Hodgkin lymphoma
  743. Tobramycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  744. Tocilizumab General information
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
    • Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe
    Indications
    Juvenile systemic arthritis
  745. Tolbutamide General information
    Section
    Hypoglycaemic agents
    • Oral > Solid: 500 mg
    Indications
    Type 2 diabetes mellitus
  746. Torasemide General information
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide for Heart failure
  747. Toripalimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 240 mg per 6 mL in vial
    Indications
    Squamous cell carcinoma of oesophagus Malignant neoplasms of nasopharynx
  748. Tramadol General information
    Section
    Opioid analgesics
    • Oral > Liquid: 100 mg per mL (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release
    • Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Chronic cancer pain
  749. Trametinib General information
    Section
    Targeted therapies
    • Oral > Solid: 0.5 mg; 2 mg
    Indications
    Other specified melanoma of skin
  750. Tranexamic acid General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Postpartum haemorrhage
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
  751. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  752. Trastuzumab emtansine General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  753. Tremelimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion
    Indications
    Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung
  754. Triamcinolone hexacetonide General information
    Section
    Medicines for juvenile joint diseases
    • Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial
    Indications
    Juvenile idiopathic arthritis
  755. Triclabendazole General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 250 mg (scored)
    Indications
    Paragonimiasis Fascioliasis
  756. Trihexyphenidyl General information
    Section
    Medicines for central nervous system disorders
    • Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)
    Indications
    Parkinson disease
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to biperiden for Parkinson disease
  757. Trimethoprim General information
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    First choice
    Infectious cystitis
  758. Triptorelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  759. Tropicamide General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
    Cycloplegic drug
  760. Tropisetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  761. Tuberculin, purified protein derivative General information
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
    Indications
    Mycobacterial diseases
  762. Tubocurarine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)
    Indications
    Muscle relaxants
  763. Typhoid vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  764. Ulipristal General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
    Indications
    Contact with health services for postcoital contraception
  765. Umeclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  766. Urea General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
    Indications
    Xerosis cutis or asteatosis
    Section
    Dermatological medicines > Moisturizers
    • Local > Topical > Cream: 5 per %
    Indications
    Atopic eczema
  767. Ustekinumab General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen
    Indications
    Psoriasis of unspecified type
  768. Valaciclovir General information
    Section
    Medicines for viral central nervous system infections
    Indications
    Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Herpes simplex infections Therapeutic equivalent to aciclovir for Varicella
  769. Valganciclovir General information
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
    • Oral > Solid > tablet: 450 mg (as hydrochloride)
    Indications
    Cytomegaloviral retinitis
  770. Valproic acid (sodium valproate) General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Epilepsy or seizures Status epilepticus
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)
    Indications
    Bipolar or related disorders
  771. Valsartan + amlodipine + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg
    Indications
    Essential hypertension
  772. Vancomycin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
    • Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    First choice
    Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis
    Second choice
    Intestinal infections due to Clostridioides difficile Neutropaenia (high-risk)
    Other indications
    Methicillin resistant Staphylococcus aureus
  773. Varenicline General information
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Nicotine dependence
  774. Varicella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  775. Vecuronium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
    Indications
    Muscle relaxants
  776. Vemurafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  777. Verapamil General information
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Angina pectoris
    Section
    Medicines for cluster headache
    • Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)
    Indications
    Trigeminal autonomic cephalalgias
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Supraventricular tachyarrhythmia
  779. Vincristine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
    Indications
    Other specified gliomas of brain Diffuse large B-cell lymphoma, not otherwise specified Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Retinoblastoma Malignant neoplasms of kidney, except renal pelvis
  780. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    Indications
    Rhabdomyosarcoma primary site Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast
  781. Voriconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
    Indications
    Chronic pulmonary aspergillosis Invasive aspergillosis
  782. Warfarin General information
    Section
    Medicines affecting coagulation
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    Indications
    Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation Other specified diseases of arteries or arterioles
  783. Water for injection General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
    Indications
    Unspecified appropriateness of dosing or administration without injury or harm
  784. Whole blood General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  785. Xylometazoline General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL
    • Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL
    Indications
    Nasal congestion
  786. Yellow fever vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  787. Zanubrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 80 mg
    • Oral > Solid > capsule: 80 mg
    Indications
    Mantle cell lymphoma Therapeutic equivalent to ibrutinib for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  788. Zidovudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > tablet: 300 mg
    • Oral > Solid > capsule: 250 mg
    Indications
    Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
  789. Zinc sulfate General information
    Section
    Medicines for diarrhoea
    • Oral > Solid > dispersible tablet: 20 mg (scored)
    Indications
    Diarrhoea
  790. Zoledronic acid General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Osteogenesis imperfecta
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow
  791. Zuclopenthixol decanoate General information
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders